Nanomedicine Company Nanobiotix Elects Former Sanofi-Aventis Oncology
Researcher Elsa Borghi, MD, as its Medical Director
Podcast available at www.medtechmatters.com
PARIS (Business Wire EON) May 27, 2008 --
Nanobiotix,
an emerging nanomedicine company focused on cancer
therapy, announced today that it has appointed Elsa Borghi, MD,
as medical director.
Previously, Dr. Borghi worked in the R&D oncology department for Sanofi-Aventis,
one of the five largest pharmaceutical companies in the world, until the
onset of 2008, when she joined Nanobiotix. She has lead successful
clinical trials worldwide for major drugs and registration in the
Oncology field. Dr. Borghi began working in the pharmaceutical industry
in 1996 on drug safety and international reporting, mainly for oncology
and cardiovascular drugs. She began working on pivotal cancer clinical
trials in 1999, including early colon cancer, early- and late-stage
breast cancer, and prostate cancer, for which she was responsible for a
chemotherapy product registration. In addition, Dr. Borghi has worked on
soft tissue sarcoma, lung cancer and phase I studies for chemotherapies,
antisense and targeted therapies. Most of her recent work was focused on
tumor perfusion modifiers such as antivascular agents. Dr. Borghi
obtained her medical degree from the University of Cordoba School of
Medicine in March 1984 and the French equivalent in 1994 from the
University of Paris V.
“The appointment of such an experienced
clinical manager and scientific researcher as Dr. Borghi is a very
significant milestone for Nanobiotix,” said Laurent
Levy, Ph.D., chief executive officer of Nanobiotix. “With
strong preclinical work behind us, we are looking forward to the next
giant step for Nanobiotix, our first-in-man and the start of clinical
trials in the not-too-distant future. We therefore expect to benefit
from Dr. Borghi’s substantial accomplishments
related to turning promising research into approved products designed to
produce favorable outcomes for patients.”
ABOUT NANOBIOTIX
Nanobiotix is an emerging nanomedicine company combining dramatic
advances in nanotechnology and molecular biology to develop nanoXray™
- a technology platform that is expected to be turned ‘on’
and ‘off’
outside the body to selectively treat a variety of cancers safely
and noninvasively. Use of nanoXray is intended to resolve
radiation therapy’s biggest drawback:
destruction of healthy tissue and its subsequent deleterious side
effects when a high dose of x-ray is necessary. The core of a nanoXray
nanoparticle is an inactive and inert substance—not
a drug—that can subsequently be activated in
order to locally (intratumor) increase the dose of x-ray, which is then
expected to lead to higher efficiency. After nanoXray nanoparticles
accumulate in the target tissues, a standard x-ray is applied that is
intended to generate a local therapeutic effect, designed to destroy
only the targeted tumor cells. This mechanism suggests total
control of the intended therapeutic effect.
Post Comment:
Trackback URL: http://eon.businesswire.com/pingpr.php/U3F1YS1IYWxmLUZhbHUtRmFsdS1DcmFzLVplcm8=
Bookmark -
Del.icio.us |
Digg |
Furl It |
Spurl |
RawSugar |
Simpy |
Shadows |
Blink It |
My Web
|
